thalidomide has been researched along with Viremia in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Viremia: The presence of viruses in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "we started a prospective, open label trial of retreatment of very-difficult-to-treat genotype 1 chronic hepatitis C patients (CHC) patients, who had failed to respond to the (Peg-IFN/RBV), with a triple therapy consisting in these same antivirals plus thalidomide 200 mg/day (the TRITAL study)." | 9.15 | Thalidomide with peginterferon alfa-2b and ribavirin in the treatment of non-responders genotype 1 chronic hepatitis C patients: proof of concept. ( Dorantes, B; Eslam, M; Gallego-Durán, R; García-Collado, C; Grande, L; Morillo, R; Paradas, C; Pardo-Yules, B; Romero-Gómez, M, 2011) |
| "we started a prospective, open label trial of retreatment of very-difficult-to-treat genotype 1 chronic hepatitis C patients (CHC) patients, who had failed to respond to the (Peg-IFN/RBV), with a triple therapy consisting in these same antivirals plus thalidomide 200 mg/day (the TRITAL study)." | 5.15 | Thalidomide with peginterferon alfa-2b and ribavirin in the treatment of non-responders genotype 1 chronic hepatitis C patients: proof of concept. ( Dorantes, B; Eslam, M; Gallego-Durán, R; García-Collado, C; Grande, L; Morillo, R; Paradas, C; Pardo-Yules, B; Romero-Gómez, M, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pardo-Yules, B | 1 |
| Gallego-Durán, R | 1 |
| Eslam, M | 1 |
| García-Collado, C | 1 |
| Grande, L | 1 |
| Paradas, C | 1 |
| Morillo, R | 1 |
| Dorantes, B | 1 |
| Romero-Gómez, M | 1 |
| Kim, JH | 1 |
| Goulston, C | 1 |
| Sanders, S | 1 |
| Lampas, M | 1 |
| Zangari, M | 1 |
| Tricot, G | 1 |
| Hanson, KE | 1 |
1 trial available for thalidomide and Viremia
| Article | Year |
|---|---|
Thalidomide with peginterferon alfa-2b and ribavirin in the treatment of non-responders genotype 1 chronic hepatitis C patients: proof of concept.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genes, Viral; Genotype; Hepacivirus; Hep | 2011 |
1 other study available for thalidomide and Viremia
| Article | Year |
|---|---|
Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation.
Topics: Aged; Antiviral Agents; Boronic Acids; Bortezomib; Cytomegalovirus; Cytomegalovirus Infections; Fema | 2012 |